Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Director David Petrie was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 19
Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026 Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026 Tillkännagivande • Jan 15
Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of Appeal Mayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters. Tillkännagivande • Jan 14
Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026 Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee. Tillkännagivande • Dec 22
Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026 Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australia Tillkännagivande • Aug 01
Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025 Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025 Tillkännagivande • Apr 10
TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract Breaches On April 8, 2025, TherapeuticsMD Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma and the Transaction Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma. The Mayne Lawsuit primarily pertains to the previously disclosed disputes between the Company and Mayne Pharma relating to certain net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto. The Mayne Lawsuit is TherapeuticsMD Inc. v. Mayne Pharma LLC, Case No. not assigned (D. Del.). Tillkännagivande • Feb 22
Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million. Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million on February 20, 2025. A cash consideration of AUD 601.22 million valued at AUD 7.4 per share will be paid by Cosette Pharmaceuticals, Inc. As part of consideration, AUD 601.22 million is paid towards common equity of Mayne Pharma Group Limited. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders and subject to court approval. The deal has been unanimously approved by the board. The expected completion of the transaction is May 21, 2025 to June 10, 2025. Jefferies Pty Ltd acted as financial advisor for Mayne Pharma Group Limited. Arnold & Porter Kaye Scholer LLP acted as legal advisor for Mayne Pharma Group Limited. Gilbert and Tobin acted as legal advisor for Mayne Pharma Group Limited. Ropes & Gray LLP acted as legal advisor for Cosette Pharmaceuticals, Inc. Corrs Chambers Westgarth acted as legal advisor for Cosette Pharmaceuticals, Inc. UBS Securities LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Santander US Capital Markets LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Reported Earnings • Aug 23
Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023) Full year 2024 results: AU$2.12 loss per share (improved from AU$3.86 loss in FY 2023). Revenue: AU$388.4m (up 112% from FY 2023). Net loss: AU$168.6m (loss narrowed 47% from FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Breakeven Date Change • May 19
No longer forecast to breakeven The 2 analysts covering Mayne Pharma Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of AU$17.8m in 2026. New consensus forecast suggests the company will make a loss of AU$2.05m in 2026. New Risk • May 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$274m Forecast net loss in 2 years: AU$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 28
First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023) First half 2024 results: AU$0.88 loss per share (improved from AU$1.38 loss in 1H 2023). Revenue: AU$187.9m (up 260% from 1H 2023). Net loss: AU$70.5m (loss narrowed 38% from 1H 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Breakeven Date Change • Feb 27
Forecast to breakeven in 2026 The 2 analysts covering Mayne Pharma Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 91% per year to 2025. The company is expected to make a profit of AU$17.8m in 2026. Average annual earnings growth of 110% is required to achieve expected profit on schedule. New Risk • Feb 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$22m net loss in 2 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Tillkännagivande • Feb 12
Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024 Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024 Board Change • Dec 07
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Anne Lockwood was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 30
Mayne Pharma Group Limited Approves Election of Anne Lockwood Mayne Pharma Group Limited at its AGM approved election of Anne Lockwood. Recent Insider Transactions • Oct 29
CEO, MD & Director recently bought €84k worth of stock On the 24th of October, Shawn O’Brien bought around 37k shares on-market at roughly €2.28 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Shawn's only on-market trade for the last 12 months. Tillkännagivande • Oct 27
Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023 Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023, at 10:00 AUS Eastern Standard Time. Location: MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St Melbourne Australia Agenda: To consider and approve the statutory reports for the financial year ended 30 June 2023; to consider and approve the election of Director; to consider and approve the remuneration report; to consider and approve the Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director; to consider and approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and to consider and approve the extension of the on-market share buy-back. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022) Full year 2023 results: AU$3.86 loss per share (further deteriorated from AU$3.20 loss in FY 2022). Revenue: AU$183.6m (down 57% from FY 2022). Net loss: AU$317.4m (loss widened 21% from FY 2022). Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$287m). Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$52m net loss in 2 years). Tillkännagivande • Aug 24
Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023 Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023 Tillkännagivande • Jul 27
Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023 Mayne Pharma Group Limited announced that Dr. Carolyn Myers will retire from the Board at the end of July 2023.Dr Myers has served as a Director of Mayne Pharma since October 2021. She was appointed to theBoard after being nominated by Mithra Pharmaceuticals SA under the terms of the license andsupply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the UnitedStates. Reported Earnings • Mar 01
First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022) First half 2023 results: AU$0.078 loss per share. Revenue: AU$101.2m (down 49% from 1H 2022). Net loss: AU$129.1m (loss widened 156% from 1H 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Tillkännagivande • Jan 14
Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million. Upcoming Dividend • Jan 11
Inaugural dividend of AU$0.065 per share Eligible shareholders must have bought the stock before 18 January 2023. Payment date: 27 January 2023. The company last paid an ordinary dividend in . The average dividend yield among industry peers is 2.6%. Buying Opportunity • Dec 14
Now 48% undervalued after recent price drop Over the last 90 days, the stock is down 38%. The fair value is estimated to be €0.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.9% over the last 3 years. Earnings per share has grown by 18%. For the next 3 years, revenue is forecast to grow by 9.2% per annum. Earnings is also forecast to grow by 92% per annum over the same time period. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO, MD & Director Shawn O’Brien was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO, MD & Director Shawn O’Brien was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 27
Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021) Full year 2022 results: AU$0.16 loss per share (down from AU$0.13 loss in FY 2021). Revenue: AU$424.8m (up 6.0% from FY 2021). Net loss: AU$263.3m (loss widened 26% from FY 2021). Over the next year, revenue is expected to shrink by 4.8% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Breakeven Date Change • Feb 28
Forecast breakeven date pushed back to 2024 The 5 analysts covering Mayne Pharma Group previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 66% per year to 2023. The company is expected to make a profit of AU$16.9m in 2024. Average annual earnings growth of 91% is required to achieve expected profit on schedule. Reported Earnings • Feb 27
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: AU$0.031 loss per share (up from AU$0.12 loss in 1H 2021). Revenue: AU$196.4m (down 5.9% from 1H 2021). Net loss: AU$50.4m (loss narrowed 72% from 1H 2021). Revenue missed analyst estimates by 4.6%. Over the next year, revenue is forecast to grow 28%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Board Change • Dec 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Director Carolyn Myers was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 31
High number of new directors Independent Non-Executive Deputy Chairman Ian Scholes was the last director to join the board, commencing their role in 2021. Executive Departure • Oct 07
Independent Non Executive Director Bruce Mathieson has left the company On the 30th of September, Bruce Mathieson's tenure as Independent Non Executive Director ended after 14.6 years in the role. As of June 2021, Bruce still personally held 105.58m shares (€19m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.92 years. Executive Departure • Oct 07
Independent Chairman Roger Corbett has left the company On the 30th of September, Roger Corbett's tenure as Independent Chairman ended after 10.7 years in the role. As of June 2021, Roger still personally held 10.44m shares (€1.9m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.92 years. Executive Departure • Oct 07
Independent Chairman Roger Corbett has left the company On the 30th of September, Roger Corbett's tenure as Independent Chairman ended after 10.7 years in the role. As of June 2021, Roger still personally held 10.44m shares (€1.9m worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.92 years. Breakeven Date Change • Sep 23
Forecast to breakeven in 2023 The 6 analysts covering Mayne Pharma Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$15.0m in 2023. Average annual earnings growth of 112% is required to achieve expected profit on schedule. Recent Insider Transactions • Sep 04
Independent Non-Executive Director recently bought €85k worth of stock On the 1st of September, Frank Condella bought around 412k shares on-market at roughly €0.21 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • Aug 28
Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: AU$400.8m (down 12% from FY 2020). Net loss: AU$208.4m (loss widened 125% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Reported Earnings • Feb 25
First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020) The company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: AU$208.8m (down 8.1% from 1H 2020). Net loss: AU$181.3m (loss widened AU$163.1m from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Feb 25
Revenue beats expectations Revenue exceeded analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 4.4%, compared to a 2.1% growth forecast for the Pharmaceuticals industry in Germany. Is New 90 Day High Low • Dec 19
New 90-day high: €0.24 The company is up 23% from its price of €0.20 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.53 per share. 
